Last reviewed · How we verify
eye drops (Phenylephrin)
Phenylephrine is an alpha-1 adrenergic agonist that constricts blood vessels in the eye to reduce redness and dilate the pupil.
Phenylephrine is an alpha-1 adrenergic agonist that constricts blood vessels in the eye to reduce redness and dilate the pupil. Used for Conjunctival hyperemia (eye redness), Mydriasis for diagnostic procedures.
At a glance
| Generic name | eye drops (Phenylephrin) |
|---|---|
| Also known as | Minims |
| Sponsor | Medical University of Graz |
| Drug class | Alpha-1 adrenergic agonist |
| Target | Alpha-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Phenylephrine works by stimulating alpha-1 adrenergic receptors on vascular smooth muscle in the conjunctiva and iris, causing vasoconstriction that reduces conjunctival hyperemia and mydriasis (pupil dilation). In ophthalmic formulations, it is used as a decongestant to relieve eye redness and as a mydriatic agent for diagnostic procedures.
Approved indications
- Conjunctival hyperemia (eye redness)
- Mydriasis for diagnostic procedures
Common side effects
- Ocular irritation
- Transient stinging or burning
- Blurred vision
- Systemic hypertension (with systemic absorption)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- eye drops (Phenylephrin) CI brief — competitive landscape report
- eye drops (Phenylephrin) updates RSS · CI watch RSS
- Medical University of Graz portfolio CI